Alzheimer's Disease and Lewy Body Disease Clinical Trial
Official title:
Rate of Alpha-synuclein in Cerebrospinal Fluid to Differentiate Patient With Alzheimer's Disease From Those With Lewy Body Disease.
Patients with memory disorders are experiencing different trends which are difficult to
predict. Moreover, the distinction between Lewy body disease and Alzheimer's disease is not
easy as both diseases can present similar symptoms. Nowadays, routine examinations exist and
can improve the diagnosis but there are not specific enough of one of those two pathologies.
Lewy body disease is characterized by the presence of particular structures in patient's
brain, called "Lewy body", composed of a protein called "alpha-synuclein". The aim of this
study is to measure the rate of alpha-synuclein in cerebrospinal fluid. This measurement
could allow us to differentiate patient with Alzheimer's disease from those with Lewy body
disease.
n/a
Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic